The home of the Audio Journal of Oncology

Tagenzyme

1 articles

Public Health

Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone

March 6, 2007

AudioMedica News Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised...

Tagenzyme

Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone

Menu

Sign up for AudioMedica.com news